Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-030519
Filing Date
2024-03-13
Accepted
2024-03-13 08:52:27
Documents
141
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 20-F sln-20231231.htm   iXBRL 20-F 4198862
2 EX-2.3 sln-ex2_3.htm EX-2.3 230023
3 EX-4.10 sln-ex4_10.htm EX-4.10 383459
4 EX-12.1 sln-ex12_1.htm EX-12.1 15455
5 EX-12.2 sln-ex12_2.htm EX-12.2 15440
6 EX-13.1 sln-ex13_1.htm EX-13.1 15718
7 EX-13.2 sln-ex13_2.htm EX-13.2 15913
8 EX-15.1 sln-ex15_1.htm EX-15.1 3854
9 EX-97.1 sln-ex97_1.htm EX-97.1 27389
10 GRAPHIC img50588744_0.jpg GRAPHIC 85230
11 GRAPHIC img171751254_0.jpg GRAPHIC 68926
12 GRAPHIC img171751254_1.jpg GRAPHIC 443825
  Complete submission text file 0000950170-24-030519.txt   17814106

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sln-20231231.xsd EX-101.SCH 1718011
143 EXTRACTED XBRL INSTANCE DOCUMENT sln-20231231_htm.xml XML 3613146
Mailing Address 72 HAMMERSMITH ROAD LONDON X0 W14 8TH
Business Address 72 HAMMERSMITH ROAD LONDON X0 W14 8TH 44-0-20-3457 6900
Silence Therapeutics plc (Filer) CIK: 0001479615 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0
Type: 20-F | Act: 34 | File No.: 001-39487 | Film No.: 24744684
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)